VarmX was founded by Pieter Reitsma in 2016.

Who are VarmX's investors?

VarmX's investors include BioGeneration Ventures, Inkef, Sound Bioventures, Ysios Capital, EIC, EQT Life Sciences, UNIIQ, BGV and 2 more.

VarmX

Founded 2016 · 36 employees on LinkedIn · 16 known investors

Find your way into VarmX

Paths you didn't know you had: your email and LinkedIn already hold routes to the VarmX team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings. The company focuses on advancing coagulation therapy for patients taking this class of blood thinners.

Biotech Healthtech Medical Devices

Founders & leadership

VarmX was founded in 2016 by Pieter Reitsma.

Pieter ReitsmaFounder

John Glasspool Chief Executive OfficerCEO of VarmX, which develops coagulation therapy for patients on Factor Xa anticoagulants. Glasspool has held executive roles in global pharmaceutical operations, including leadership of multi-billion dollar product franchises across the U.S., Europe, and emerging markets, with expertise in product development, commercialization, and business development through licensing and partnerships; he holds patents in neuroscience and cardiovascular treatment.

Investors · 16

BioGeneration Ventures✓ confirmed by VarmXNaarden

How we know: the company's own site · BioGeneration Ventures's portfolio page · a partner's Signal profile · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Inkef✓ confirmed by VarmXAmsterdam

How we know: the company's own site · Inkef's portfolio page · funding news · labiotech.eu · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Sound Bioventures✓ confirmed by VarmXMalmö

How we know: the company's own site · funding news · labiotech.eu · the VCSheet dataset · Not right? Tell us

Ysios Capital✓ confirmed by VarmXBarcelona · $5.4M – $21.6M

How we know: Ysios Capital's portfolio page · the company's own site · funding news · ysioscapital.com · the VCSheet dataset · Not right? Tell us

EIC✓ confirmed by VarmXOrinda

How we know: the company's own site · funding news · Not right? Tell us

EQT Life Sciences✓ confirmed by VarmXAmsterdam · $11M – $66M

How we know: the company's own site · funding news · labiotech.eu · Not right? Tell us

UNIIQlisted by UNIIQThe Hague

How we know: UNIIQ's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

BGVreportedSilicon Valley

How we know: funding news · Not right? Tell us

Lundbeckfonden VenturesreportedKøbenhavn

How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us

SynconareportedLondon

How we know: a partner's Signal profile · Not right? Tell us

Also in the syndicate · 6

BioGeneration Ventures (BGV)leadEuropean Innovation Council (EIC) FundInnovationQuarterInnovationQuarter (IQ)Libertatis Ergo Holding (LEH)Lundbeckfonden BioCapital

Funding

SEC filings, press & company announcements

Undisclosed amountSeries B2May 2023 · 3 sources
Sound Bioventures (lead), BioGeneration Ventures (BGV), EQT Life Sciences, European Innovation Council (EIC) Fund, Inkef, InnovationQuarter (IQ), Libertatis Ergo Holding (LEH), Lundbeckfonden BioCapital, Ysios Capital
Source ↗
Undisclosed amountSeries BJul 2020
Source ↗
Undisclosed amountSeries AJul 2018
BioGeneration Ventures (BGV) (lead), InnovationQuarter
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery - BioSpacebiospace.com · Aug 2026

VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants - BioSpacebiospace.com · Jul 2018

Frequently asked questions

What does VarmX do?: VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings. The company focuses on advancing coagulation therapy for patients taking this class of blood thinners.
Who founded VarmX?: VarmX was founded by Pieter Reitsma in 2016.
Who are VarmX's investors?: VarmX's investors include BioGeneration Ventures, Inkef, Sound Bioventures, Ysios Capital, EIC, EQT Life Sciences, UNIIQ, BGV and 2 more.